Skip to content

Erasca, Inc. ERAS In Process Research And Development Expense

In Process Research And Development Expense at other companies

iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
$296K0.0%
Gilead Sciences logo
Gilead SciencesGILD
$107M-57.7%
Campbell Soup logo
Campbell SoupCPB
$6M-82.9%
Eli Lilly logo
Eli LillyLLY
$584M-62.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$101.9M+728%
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC
$296K0.0%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept eras:InProcessResearchAndDevelopmentExpense.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s in process research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s in process research and development expense?
Erasca, Inc. (ERAS) reported in process research and development expense of $150M in Q1 2026.
What does in process research and development expense mean?
Represents the costs associated with acquired research and development projects that have not yet reached technological feasibility. These expenses are typically incurred during business combinations or asset acquisitions where the acquired technology has no alternative future use. Monitoring this metric helps investors understand the capital allocated to inorganic pipeline expansion versus internal R&D efforts.